A presumption of the logo of Novo Nordisk astatine the company's bureau successful Bagsvaerd, connected the outskirts of Copenhagen, Denmark, March 8, 2024.
Tom Little | Reuters
Novo Nordisk said connected Thursday it agreed to bargain Akero Therapeutics for up to $5.2 billion, giving the Danish drugmaker entree to the U.S.-based company's experimental liver illness drug.
Akero's experimental drug, efruxifermin, is being studied successful patients with terrible scarring oregon cirrhosis owed to a benignant of fatty liver illness known arsenic metabolic dysfunction-associated steatohepatitis (MASH).
Under the deal, Novo would wage Akero shareholders $54 per stock successful currency and an further $6 per stock upon afloat U.S. support of efruxifermin for attraction of compensated cirrhosis owed to MASH by June 30, 2031, the companies said.
English (US) ·